AR083542A1 - Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasa - Google Patents
Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasaInfo
- Publication number
- AR083542A1 AR083542A1 ARP110103927A ARP110103927A AR083542A1 AR 083542 A1 AR083542 A1 AR 083542A1 AR P110103927 A ARP110103927 A AR P110103927A AR P110103927 A ARP110103927 A AR P110103927A AR 083542 A1 AR083542 A1 AR 083542A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- unsubstituted
- trifluoromethyl
- fluorine
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40587610P | 2010-10-22 | 2010-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083542A1 true AR083542A1 (es) | 2013-03-06 |
Family
ID=44993878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103927A AR083542A1 (es) | 2010-10-22 | 2011-10-24 | Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasa |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2629851A1 (fr) |
| JP (1) | JP2013540159A (fr) |
| KR (1) | KR20130142137A (fr) |
| CN (1) | CN103260703A (fr) |
| AR (1) | AR083542A1 (fr) |
| AU (1) | AU2011316970A1 (fr) |
| BR (1) | BR112013009858A2 (fr) |
| CA (1) | CA2815350A1 (fr) |
| IL (1) | IL225769A0 (fr) |
| RU (1) | RU2013123275A (fr) |
| TW (1) | TW201305136A (fr) |
| WO (1) | WO2012054716A1 (fr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| WO2014152588A1 (fr) * | 2013-03-15 | 2014-09-25 | Araxes Pharma Llc | Inhibiteurs covalents de k-ras g12c |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| US9624170B2 (en) | 2013-12-26 | 2017-04-18 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049568A1 (fr) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Méthodes et compositions permettant l'inhibition de la ras |
| AR102094A1 (es) | 2014-09-25 | 2017-02-01 | Araxes Pharma Llc | Inhibidores de proteínas kras con una mutación g12c |
| EP3279191B1 (fr) | 2015-03-30 | 2020-09-02 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| EP3283462B1 (fr) | 2015-04-15 | 2020-12-02 | Araxes Pharma LLC | Inhibiteurs tricycliques condensés de kras et procédés pour les utiliser |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017058768A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
| EP3356353A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
| WO2017058792A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
| WO2017058805A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
| WO2017058902A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
| WO2017058915A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
| WO2017058807A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
| WO2017070256A2 (fr) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Méthode de criblage d'inhibiteurs de ras |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017143283A1 (fr) | 2016-02-19 | 2017-08-24 | Abide Therapeutics, Inc. | Sonde de présence de monoacylglycérol lipase radiomarquée |
| WO2017172979A1 (fr) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Composés quinazoline substitués et procédés d'utilisation |
| EP3438109B1 (fr) | 2016-03-31 | 2021-08-25 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
| US10323026B2 (en) * | 2016-03-31 | 2019-06-18 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2019529484A (ja) | 2016-09-29 | 2019-10-17 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤 |
| WO2018068017A1 (fr) | 2016-10-07 | 2018-04-12 | Araxes Pharma Llc | Composés hétérocycliques en tant qu'inhibiteurs de ras et leurs procédés d'utilisation |
| WO2018140514A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer |
| WO2018140512A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| EP3573971A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer |
| US11358959B2 (en) | 2017-01-26 | 2022-06-14 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| CN110831933A (zh) | 2017-05-25 | 2020-02-21 | 亚瑞克西斯制药公司 | 喹唑啉衍生物作为突变kras、hras或nras的调节剂 |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| EP3630746A1 (fr) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Composés et leurs procédés d'utilisation pour le traitement du cancer |
| JP7189143B2 (ja) | 2017-09-29 | 2022-12-13 | 武田薬品工業株式会社 | 複素環化合物 |
| TW201936602A (zh) * | 2017-11-28 | 2019-09-16 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
| EP3856179A1 (fr) | 2018-09-28 | 2021-08-04 | Janssen Pharmaceutica N.V. | Modulateurs de la monoacylglycérol lipase |
| CN109879797A (zh) * | 2019-01-10 | 2019-06-14 | 安徽昊帆生物有限公司 | N-苄基-四氢吡啶类化合物及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9812037D0 (en) * | 1998-06-04 | 1998-07-29 | Pfizer Ltd | Piperidones |
| US8106208B2 (en) * | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
| FR2915198B1 (fr) * | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| EP2283126A1 (fr) * | 2008-04-25 | 2011-02-16 | Janssen Pharmaceutica, N.V. | Structure cristalline de la monoacylglycérol lipase (mgll) |
| ES2880623T3 (es) * | 2009-04-02 | 2021-11-25 | Merck Patent Gmbh | Derivados de piperidina y piperazina como inhibidores de autotaxina |
| TW201103931A (en) * | 2009-04-22 | 2011-02-01 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
-
2011
- 2011-10-20 RU RU2013123275/04A patent/RU2013123275A/ru not_active Application Discontinuation
- 2011-10-20 CN CN201180061809XA patent/CN103260703A/zh active Pending
- 2011-10-20 CA CA2815350A patent/CA2815350A1/fr not_active Abandoned
- 2011-10-20 BR BR112013009858A patent/BR112013009858A2/pt not_active IP Right Cessation
- 2011-10-20 EP EP11784828.3A patent/EP2629851A1/fr not_active Withdrawn
- 2011-10-20 AU AU2011316970A patent/AU2011316970A1/en not_active Abandoned
- 2011-10-20 WO PCT/US2011/057085 patent/WO2012054716A1/fr active Application Filing
- 2011-10-20 KR KR1020137012911A patent/KR20130142137A/ko not_active Application Discontinuation
- 2011-10-20 JP JP2013535086A patent/JP2013540159A/ja active Pending
- 2011-10-21 TW TW100138198A patent/TW201305136A/zh unknown
- 2011-10-24 AR ARP110103927A patent/AR083542A1/es not_active Application Discontinuation
-
2013
- 2013-04-15 IL IL225769A patent/IL225769A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103260703A (zh) | 2013-08-21 |
| WO2012054716A1 (fr) | 2012-04-26 |
| AU2011316970A1 (en) | 2013-05-09 |
| CA2815350A1 (fr) | 2012-04-26 |
| RU2013123275A (ru) | 2014-11-27 |
| TW201305136A (zh) | 2013-02-01 |
| KR20130142137A (ko) | 2013-12-27 |
| EP2629851A1 (fr) | 2013-08-28 |
| BR112013009858A2 (pt) | 2016-07-26 |
| IL225769A0 (en) | 2013-06-27 |
| JP2013540159A (ja) | 2013-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083542A1 (es) | Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasa | |
| AR082891A1 (es) | Di-azetidinil diamidas como inhibidores de monoacilglicerol lipasas | |
| AR083180A1 (es) | Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| AR091858A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| RU2018121834A (ru) | Новое соединение бифенила или его соль | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR064452A1 (es) | Derivados de 1,2,4 oxadiazol-indol,composiciones farmaceuticas que los comprenden y usos en trastornos asociados a receptores s1p1. | |
| AR076381A1 (es) | Azetidinil diamidas como inhibidores de monoacilglicerol lipasa | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR083543A1 (es) | Diamidas de amino-pirrolidin-azetidinas, composiciones farmaceuticas que las contienen y uso de las mismas para tratar dolores inflamatorios | |
| AR061243A1 (es) | Derivados de n-2-feniletil-carboxamidas, composiciones para el control de mocroorganismos fitopatogenicos que los comprenden y un metodo de control o prevencion de infestacion de plantas utiles que los emplea. | |
| AR070395A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il- amina | |
| PE20141372A1 (es) | Nuevos derivados dihidroquinolina-2-ona | |
| NI200800008A (es) | Métodos para la neuroprotección | |
| AR112789A2 (es) | COMPUESTOS INHIBIDORES DE DOPAMINA-b-HIDROXILASA | |
| DOP2010000227A (es) | Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion terapeutica | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR059590A1 (es) | Inhibidores de quinasa basados en la hidantoina | |
| RS52261B (en) | AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR | |
| AR064760A1 (es) | Derivados de diazol como inhibidores de la eg-5 | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |